Daxor. has filed a patent for a system that automatically analyzes a patient’s blood volume status. The system includes a hematocrit monitor, processors, and a user interface to gather data, calculate ideal blood volume, and provide ongoing monitoring and updates without the need for tracer measurements. GlobalData’s report on Daxor gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Daxor, Sleep quality monitoring was a key innovation area identified from patents. Daxor's grant share as of January 2024 was 54%. Grant share is based on the ratio of number of grants to total number of patents.
Blood volume monitoring system for patient treatment recommendations
A newly filed patent (Publication Number: US20240016421A1) describes a system for automatically analyzing a living patient's blood, utilizing a hematocrit (Hct) monitor, processors, memory, and a user interface. The system gathers data from the user interface and the Hct monitor, calculates ideal and actual blood volume parameters, displays and stores results, and updates values based on later Hct measurements without tracer concentration measurements. The system can provide guidance for conditions like heart failure, syncope, anemia, and polycythemia, triggering alerts based on measured Hct values.
Furthermore, the patent outlines a method for analyzing blood and treating patients based on the system's capabilities. By setting thresholds for blood volume values, the system can trigger alerts when updated measurements pass these thresholds, leading to specific treatment recommendations for conditions like heart failure, syncope, anemia, and polycythemia. The alerts can include guidance for treatments such as consultations, additional testing, medication adjustments, and lifestyle recommendations, tailored to the patient's specific condition and blood volume parameters. Additionally, the system can indicate improvements in the patient's condition, prompting recommendations for treatment cessation or confirmatory testing.
To know more about GlobalData’s detailed insights on Daxor, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.